Actively Recruiting
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Led by Sun Yat-sen University · Updated on 2024-12-12
45
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
CONDITIONS
Official Title
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed type AB or B1-3 thymoma.
- Measurable disease as defined by RECIST criteria.
- Unresectable or recurrent thymoma confined to chest and neck area.
- Age between 18 and 70 years, any sex.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- No prior chest radiation.
- Adequate organ functions.
- Written informed consent obtained.
You will not qualify if you...
- Contraindications to methylprednisolone.
- History of or concurrent malignancy.
- Active infection, myocardial infarction within 6 months, or symptomatic heart disease.
- Pregnant or lactating women.
- Bleeding disorders.
- Recent participation in other clinical trials.
- Drug abuse or severe alcoholism.
- Uncontrolled seizures or mental disorders.
- Severe allergies or specific sensitivities.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun yat-sen University Cancer Center
Guanzhou, Guangdong, China, 510000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here